This is a non-interventional prospective observational study in patients receiving Vedolizumab therapy for IBD. Sites will enroll patients with moderately to severely active IBD (UC or CD), initiating or ongoing IV induction treatment with vedolizu...

Klinische Forschung - 14.07.2022 - 31.12.2023

Automatisch geschlossen

Projektleitung: Brand Stephan
Mitarbeiter/innen: Eckhold Annika, König Marius, Krieger-Grübel Claudia

A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Crohn's Disease

Klinische Forschung - 07.06.2022 - 31.12.2024

Laufend

Projektleitung: Brand Stephan
Mitarbeiter/innen: Eckhold Annika, Krieger-Grübel Claudia, König Marius

The Crohn’s disease exclusion diet (CDED) for induction and maintenance of remission in Crohn’s patients with or without additional medical therapy. An open label observational trial

Klinische Forschung - 01.06.2022 - 30.12.2023

Automatisch geschlossen

Projektleitung: Krieger-Grübel Claudia
Mitarbeiter/innen: Brand Stephan, Eckhold Annika

This is a double-blind, randomised, multicentre, placebo-controlled, comparative phase IIb dose-finding and efficacy trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will serve to compare...

Klinische Forschung - 01.06.2022 - 31.12.2024

Laufend

Projektleitung: Brand Stephan
Mitarbeiter/innen: Eckhold Annika, König Marius, Krieger-Grübel Claudia, Truniger Samuel

A Phase 2, Multicenter, Dose-finding, Double blinded, Pla-cebo- Controlled Study to Evaluate the Safety and Effi-cacy of Efavaleukin Alfa Induc-tion Therapy in Patients with Mederatly to Severely UC

Klinische Forschung - 25.04.2022 - 31.12.2023

Automatisch geschlossen

Projektleitung: Brand Stephan
Mitarbeiter/innen: Eckhold Annika, Krieger-Grübel Claudia

This is a national multi-center cohort confirmatory study which is designed as a prospective observational trial combined with retrospective data collection. Prospective data are collected through a patient questionnaire and assessment of blood sam...

Klinische Forschung - 20.01.2022 - 30.03.2023

Automatisch geschlossen

Projektleitung: Brand Stephan
Mitarbeiter/innen: König Marius, Dütschler Joel, Krieger-Grübel Claudia, Eckhold Annika, Truniger Samuel, Frei Nicola Fabian, Albrich Werner

A Phase 3b, Randomized, Double-Blind, Parallel-Arm, Placebo- and Active- Controlled Treat-Through Study of Mirikizumab and Vedolizumab in participants with Moderately to Severely Active Ulcerative Colitis

Klinische Forschung - 01.02.2021 - 01.01.2024

Abgeschlossen

Projektleitung: Brand Stephan
Mitarbeiter/innen: Smolders Jolijn, Krieger-Grübel Claudia

A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 3

Klinische Forschung - 29.01.2021 - 01.12.2024

Laufend

Projektleitung: Brand Stephan
Mitarbeiter/innen: Krieger-Grübel Claudia, Smolders Jolijn

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulcerative Colitis

Klinische Forschung - 01.01.2019 - 01.08.2020

Abgeschlossen

Projektleitung: Sulz Michael
Mitarbeiter/innen: Brand Stephan, Krieger-Grübel Claudia, Smolders Jolijn

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn's Disease

Klinische Forschung - 01.01.2019 - 01.12.2022

Automatisch geschlossen

Projektleitung: Brand Stephan
Mitarbeiter/innen: Sulz Michael, Smolders Jolijn, Krieger-Grübel Claudia

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 1

Klinische Forschung - 01.01.2018 - 01.02.2021

Abgeschlossen

Projektleitung: Brand Stephan
Mitarbeiter/innen: Krieger-Grübel Claudia, Sulz Michael, Smolders Jolijn

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 2

Klinische Forschung - 01.01.2018 - 01.06.2021

Automatisch geschlossen

Projektleitung: Brand Stephan
Mitarbeiter/innen: Sulz Michael, Krieger-Grübel Claudia, Smolders Jolijn

A MULTICENTER, MULTI-NATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, PHASE IIA STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF AN ANTHOCYANIN RICH EXTRACT (ACRE) IN PATIENTS WITH ULCERATIVE COLITIS.

Klinische Forschung - 01.01.2018 - 01.07.2021

Abgeschlossen

Projektleitung: Brand Stephan
Mitarbeiter/innen: Stillhard Roman, Sulz Michael, Krieger-Grübel Claudia, Smolders Jolijn

A Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study of Amiselimod (MT-1303) in the Induction and Maintenance of Clinical Response and Remission in Subjects With Moderate to Severe Ulcerative Colitis

Klinische Forschung - 01.06.2017 - 27.09.2022

Automatisch geschlossen

Mitarbeiter/innen: Knellwolf Christina, Dora Barbara, Krieger-Grübel Claudia, Sulz Michael

A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of mongersen (GED-0301) for the treatment of subjects with active Crohn’s disease.

Klinische Forschung - 01.12.2016 - 01.12.2018

Abgeschlossen

Mitarbeiter/innen: Dora Barbara, Knellwolf Christina, Krieger-Grübel Claudia, Sulz Michael

Randomized, double-blind, double-dummy, placebo-controlled, Phase III clinical trial on the efficacy and safety of a 48-weeks treatment with gastroresistant phosphatidylcholine (LT-02) versus placebo versus mesalamine for maintenance of remission in...

Klinische Forschung - 01.12.2016 - 01.12.2018

Abgeschlossen

Mitarbeiter/innen: Dora Barbara, Knellwolf Christina, Krieger-Grübel Claudia, Sulz Michael

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis

Klinische Forschung - 01.12.2016 - 01.12.2018

Automatisch geschlossen

Mitarbeiter/innen: Dora Barbara, Knellwolf Christina, Krieger-Grübel Claudia, Sulz Michael

Entyvio (vedolizumab) long-term safety study: An international observational prospective cohort study comparing vedolizumab to other biologic agents in patients with ulcerative colitis or Crohn’s Disease. This is a prospective, observational, multi-...

Klinische Forschung - 28.07.2016 - 28.06.2022

Automatisch geschlossen

Projektleitung: Brand Stephan
Mitarbeiter/innen: Dora Barbara, Knellwolf Christina, Sulz Michael, Krieger-Grübel Claudia

Randomized, double-blind, double-dummy, placebo-controlled, Phase III clinical trial on the efficacy and safety of a 12-weeks add-on treatment with LT-02 (gastro-resistant phosphatidylcholine granules) vs. placebo in patients with ulcerative colitis...

Klinische Forschung - 01.03.2016 - 31.12.2017

Abgebrochen

Mitarbeiter/innen: Dora Barbara, Knellwolf Christina, Sulz Michael, Krieger-Grübel Claudia

Gastroösophageale Refluxerkrankung (GERD) mit persistierenden Symptomen (d. h. Sodbrennen und Regurgitation) trotz Einnahme einer stabilen Dosis eines Protonenpumpenhemmers (PPI). M0003 wird als mögliche Behandlung für gastroösophagealen Reflux (GE...

Klinische Forschung - 01.05.2011 - 30.09.2011

Automatisch geschlossen

Projektleitung: Borovicka Jan
Mitarbeiter/innen: Krieger-Grübel Claudia, Künzler-Heule Patrizia